The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
there's this compound from Amgen it's called just right now it's just a code it's like AMG 133 but um it's like tepati in the sense that targets both glp1 and Gip so it's a dual dual dual uh targeted but unlike tepati which activates the Gip receptor this amen compound inhibits it
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.